Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK615915A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subjects receiving treatment sequence 1: Part 1 | EXPERIMENTAL | Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms. |
| Subjects receiving treatment sequence 2: Part 1 | EXPERIMENTAL | Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo. |
| Subjects receiving treatment sequence 1: Part 2 | EXPERIMENTAL | Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms. |
| Subjects receiving treatment sequence 2: Part 2 | EXPERIMENTAL | Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo. |
| Subjects receiving GSK615915A: Part 3 | EXPERIMENTAL | Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms. |
| Subjects receiving placebo: Part 3 | EXPERIMENTAL | Eligible subjects will receive placebo. |
| Name | Type | Description |
|---|---|---|
| GSK615915A | DRUG | GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler. |
| Placebo | DRUG | Subjects will also receive placebo inhaler. |
Inclusion Criteria: * Women of non-child bearing potential. * Body weight = 50 kg (110 lbs) for men and = 45 kg for women and Body Mass Index (BMI) within the range 19.0-30.0 kg/m² * The subject is a current non-smoker who has not used any tobacco products in the last 12 months with a pack history ...
GSK615915A is an investigational small molecule being developed for bronchospasm, a condition involving the narrowing of airways in the lungs. It is currently in Phase 1 clinical development, meaning it is still being tested in early-stage human trials and has not yet been approved for any use.
GSK615915A is being developed by GSK plc, a global biopharmaceutical company. GSK plc is publicly traded under the ticker symbol GSK. The drug is an investigational small molecule intended for the treatment of bronchospasm.
GSK615915A is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for bronchospasm, and its Phase 1 trial has been completed.
GSK615915A has been studied in one clinical trial, identified as NCT00400660, titled 'A First Time In Human Study To Assess The Compound GSK615915'. This Phase 1 trial was conducted in the United Kingdom and enrolled 46 participants, including healthy volunteers. The trial is now completed.
GSK615915A is the drug name used in the clinical trial record, while GSK615915 appears in the trial title. These names refer to the same investigational compound being developed by GSK plc for bronchospasm. The trial NCT00400660 studied this compound in healthy volunteers.